Skip to main content
. 2021 May 29;15:11795468211015230. doi: 10.1177/11795468211015230

Figure 1.

Figure 1.

(A) Cardiologists’ reasons for the increase in number of patients seeking care at their amyloidosis center over previous year and (B) cardiologists’ aspirations/vision for their amyloidosis center in the future.

ATTR-ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR-CM, transthyretin amyloid cardiomyopathy.